Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2017 | Pages:
1247 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Head And Neck Cancer - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Head And Neck Cancer - Pipeline Review, H1 2017, provides an overview of the Head And Neck Cancer (Oncology) pipeline landscape. Head and Neck Cancer is a cancer that arises in the head or neck region (in the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx). The common symptoms of cancer of the head and neck include persistent pain in the throat, pain or difficulty with swallowing, persistent hoarseness or a change in voice, pain in the ear and bleeding in the mouth or throat. The disease may be controlled by chemotherapy and radiation therapy. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Head And Neck Cancer - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Head And Neck Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Head And Neck Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Head And Neck Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 18, 87, 98, 5, 92, 17 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 11, 6, 1, 15 and 3 molecules, respectively. Head And Neck Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Head And Neck Cancer (Oncology). - The pipeline guide reviews pipeline therapeutics for Head And Neck Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Head And Neck Cancer (Oncology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Head And Neck Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Head And Neck Cancer (Oncology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Head And Neck Cancer (Oncology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Head And Neck Cancer (Oncology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 Introduction 9 Head And Neck Cancer - Overview 10 Head And Neck Cancer - Therapeutics Development 11 Head And Neck Cancer - Therapeutics Assessment 51 Head And Neck Cancer - Companies Involved in Therapeutics Development 75 Head And Neck Cancer - Drug Profiles 167 Head And Neck Cancer - Dormant Projects 1190 Head And Neck Cancer - Discontinued Products 1200 Head And Neck Cancer - Product Development Milestones 1202 Appendix 1211
List of Tables
Number of Products under Development for Head And Neck Cancer, H1 2017 46 Number of Products under Development by Companies, H1 2017 48 Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017 49 Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017 50 Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017 51 Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017 52 Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017 53 Number of Products under Development by Companies, H1 2017 (Contd..6), H1 2017 54 Number of Products under Development by Companies, H1 2017 (Contd..7), H1 2017 55 Number of Products under Development by Companies, H1 2017 (Contd..8), H1 2017 56 Number of Products under Development by Companies, H1 2017 (Contd..9), H1 2017 57 Number of Products under Development by Companies, H1 2017 (Contd..10), H1 2017 58 Number of Products under Development by Companies, H1 2017 (Contd..11), H1 2017 59 Number of Products under Development by Universities/Institutes, H1 2017 60 Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017 62 Products under Development by Companies, H1 2017 63 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 64 Products under Development by Companies, H1 2017 (Contd..2), H1 2017 65 Products under Development by Companies, H1 2017 (Contd..3), H1 2017 66 Products under Development by Companies, H1 2017 (Contd..4), H1 2017 67 Products under Development by Companies, H1 2017 (Contd..5), H1 2017 68 Products under Development by Companies, H1 2017 (Contd..6), H1 2017 69 Products under Development by Companies, H1 2017 (Contd..7), H1 2017 70 Products under Development by Companies, H1 2017 (Contd..8), H1 2017 71 Products under Development by Companies, H1 2017 (Contd..9), H1 2017 72 Products under Development by Companies, H1 2017 (Contd..10), H1 2017 73 Products under Development by Companies, H1 2017 (Contd..11), H1 2017 74 Products under Development by Companies, H1 2017 (Contd..12), H1 2017 75 Products under Development by Companies, H1 2017 (Contd..13), H1 2017 76 Products under Development by Companies, H1 2017 (Contd..14), H1 2017 77 Products under Development by Companies, H1 2017 (Contd..15), H1 2017 78 Products under Development by Companies, H1 2017 (Contd..16), H1 2017 79 Products under Development by Companies, H1 2017 (Contd..17), H1 2017 80 Products under Development by Companies, H1 2017 (Contd..18), H1 2017 81 Products under Development by Companies, H1 2017 (Contd..19), H1 2017 82 Products under Development by Universities/Institutes, H1 2017 83 Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017 84 Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017 85 Number of Products by Stage and Target, H1 2017 87 Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017 88 Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017 89 Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017 90 Number of Products by Stage and Target, H1 2017 (Contd..4), H1 2017 91 Number of Products by Stage and Target, H1 2017 (Contd..5), H1 2017 92 Number of Products by Stage and Target, H1 2017 (Contd..6), H1 2017 93 Number of Products by Stage and Target, H1 2017 (Contd..7), H1 2017 94 Number of Products by Stage and Target, H1 2017 (Contd..8), H1 2017 95 Number of Products by Stage and Mechanism of Action, H1 2017 97 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017 98 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017 99 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017 100 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4), H1 2017 101 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..5), H1 2017 102 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..6), H1 2017 103 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..7), H1 2017 104 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..8), H1 2017 105 Number of Products by Stage and Route of Administration, H1 2017 107 Number of Products by Stage and Molecule Type, H1 2017 109 Head And Neck Cancer - Pipeline by 3SBio Inc, H1 2017 110 Head And Neck Cancer - Pipeline by 4SC AG, H1 2017 110 Head And Neck Cancer - Pipeline by AB Science SA, H1 2017 111 Head And Neck Cancer - Pipeline by AbbVie Inc, H1 2017 111 Head And Neck Cancer - Pipeline by Abion Inc, H1 2017 112 Head And Neck Cancer - Pipeline by Accelerated Pharma Inc, H1 2017 112 Head And Neck Cancer - Pipeline by Acceleron Pharma Inc, H1 2017 113 Head And Neck Cancer - Pipeline by Adaptimmune Therapeutics Plc, H1 2017 113 Head And Neck Cancer - Pipeline by Aduro BioTech Inc, H1 2017 114 Head And Neck Cancer - Pipeline by Advaxis Inc, H1 2017 114 Head And Neck Cancer - Pipeline by Advenchen Laboratories LLC, H1 2017 115 Head And Neck Cancer - Pipeline by Affimed GmbH, H1 2017 115 Head And Neck Cancer - Pipeline by Altor BioScience Corp, H1 2017 116 Head And Neck Cancer - Pipeline by Ambrx Inc, H1 2017 116 Head And Neck Cancer - Pipeline by amcure GmbH, H1 2017 117 Head And Neck Cancer - Pipeline by Amgen Inc, H1 2017 117 Head And Neck Cancer - Pipeline by arGEN-X BV, H1 2017 118 Head And Neck Cancer - Pipeline by ArQule Inc, H1 2017 118 Head And Neck Cancer - Pipeline by Array BioPharma Inc, H1 2017 119 Head And Neck Cancer - Pipeline by Aspyrian Therapeutics Inc, H1 2017 119 Head And Neck Cancer - Pipeline by Astellas Pharma Inc, H1 2017 120 Head And Neck Cancer - Pipeline by AstraZeneca Plc, H1 2017 121 Head And Neck Cancer - Pipeline by Atara Biotherapeutics Inc, H1 2017 122 Head And Neck Cancer - Pipeline by ATLAB Pharma SAS, H1 2017 122 Head And Neck Cancer - Pipeline by AVEO Pharmaceuticals Inc, H1 2017 123 Head And Neck Cancer - Pipeline by Bayer AG, H1 2017 124 Head And Neck Cancer - Pipeline by BeiGene Ltd, H1 2017 124 Head And Neck Cancer - Pipeline by Benitec Biopharma Ltd, H1 2017 125 Head And Neck Cancer - Pipeline by Beta Pharma Inc, H1 2017 125 Head And Neck Cancer - Pipeline by Bexion Pharmaceuticals LLC, H1 2017 126 Head And Neck Cancer - Pipeline by BioDiem Ltd, H1 2017 126 Head And Neck Cancer - Pipeline by Biomics Biotechnologies Co Ltd, H1 2017 127 Head And Neck Cancer - Pipeline by Bionovis SA, H1 2017 127 Head And Neck Cancer - Pipeline by BioNTech AG, H1 2017 128 Head And Neck Cancer - Pipeline by Biotest AG, H1 2017 128 Head And Neck Cancer - Pipeline by Biothera Pharmaceutical Inc, H1 2017 129 Head And Neck Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2017 129 Head And Neck Cancer - Pipeline by Boston Biomedical Inc, H1 2017 130 Head And Neck Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2017 130 Head And Neck Cancer - Pipeline by CBT Pharmaceuticals Inc, H1 2017 131 Head And Neck Cancer - Pipeline by Celgene Corp, H1 2017 131 Head And Neck Cancer - Pipeline by Cell Medica Ltd, H1 2017 132 Head And Neck Cancer - Pipeline by Cellceutix Corp, H1 2017 132 Head And Neck Cancer - Pipeline by Celldex Therapeutics Inc, H1 2017 133 Head And Neck Cancer - Pipeline by Celprogen Inc, H1 2017 133 Head And Neck Cancer - Pipeline by Centrose LLC, H1 2017 134 Head And Neck Cancer - Pipeline by Corvus Pharmaceuticals Inc, H1 2017 134 Head And Neck Cancer - Pipeline by Cristal Therapeutics BV, H1 2017 135 Head And Neck Cancer - Pipeline by Critical Outcome Technologies Inc, H1 2017 135 Head And Neck Cancer - Pipeline by CytImmune Sciences Inc, H1 2017 136 Head And Neck Cancer - Pipeline by Daiichi Sankyo Company Ltd, H1 2017 136 Head And Neck Cancer - Pipeline by Denceptor Therapeutics Ltd, H1 2017 137 Head And Neck Cancer - Pipeline by DNJ Pharma Inc, H1 2017 137 Head And Neck Cancer - Pipeline by Dynavax Technologies Corp, H1 2017 138 Head And Neck Cancer - Pipeline by Eisai Co Ltd, H1 2017 138 Head And Neck Cancer - Pipeline by Eleven Biotherapeutics Inc, H1 2017 139 Head And Neck Cancer - Pipeline by Eli Lilly and Company, H1 2017 139 Head And Neck Cancer - Pipeline by Etubics Corp, H1 2017 140 Head And Neck Cancer - Pipeline by Eureka Therapeutics Inc, H1 2017 140 Head And Neck Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017 141 Head And Neck Cancer - Pipeline by Five Prime Therapeutics Inc, H1 2017 141 Head And Neck Cancer - Pipeline by Forty Seven Inc, H1 2017 142 Head And Neck Cancer - Pipeline by Fujifilm Corp, H1 2017 142 Head And Neck Cancer - Pipeline by G&E Herbal Biotechnology Co Ltd, H1 2017 143 Head And Neck Cancer - Pipeline by Galectin Therapeutics Inc, H1 2017 143 Head And Neck Cancer - Pipeline by Genelux Corp, H1 2017 144 Head And Neck Cancer - Pipeline by GeneSegues Inc, H1 2017 144 Head And Neck Cancer - Pipeline by Genexine Inc, H1 2017 145 Head And Neck Cancer - Pipeline by Genmab A/S, H1 2017 145 Head And Neck Cancer - Pipeline by GlaxoSmithKline Plc, H1 2017 146 Head And Neck Cancer - Pipeline by Glenmark Pharmaceuticals Ltd, H1 2017 147 Head And Neck Cancer - Pipeline by Gliknik Inc, H1 2017 147 Head And Neck Cancer - Pipeline by Glycotope GmbH, H1 2017 148 Head And Neck Cancer - Pipeline by Griffith University, H1 2017 148 Head And Neck Cancer - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017 149 Head And Neck Cancer - Pipeline by Hookipa Biotech AG, H1 2017 149 Head And Neck Cancer - Pipeline by Horizon Pharma Plc, H1 2017 150 Head And Neck Cancer - Pipeline by Hutchison China MediTech Ltd, H1 2017 150 Head And Neck Cancer - Pipeline by Ignyta Inc, H1 2017 151 Head And Neck Cancer - Pipeline by Immunocore Ltd, H1 2017 151 Head And Neck Cancer - Pipeline by Immunomedics Inc, H1 2017 152 Head And Neck Cancer - Pipeline by Immunovaccine Inc, H1 2017 152 Head And Neck Cancer - Pipeline by Immunovative Therapies Ltd, H1 2017 153 Head And Neck Cancer - Pipeline by Incyte Corp, H1 2017 153 Head And Neck Cancer - Pipeline by Infinity Pharmaceuticals Inc, H1 2017 154 Head And Neck Cancer - Pipeline by Innate Pharma SA, H1 2017 154 Head And Neck Cancer - Pipeline by Inovio Pharmaceuticals Inc, H1 2017 155 Head And Neck Cancer - Pipeline by InteRNA Technologies BV, H1 2017 155 Head And Neck Cancer - Pipeline by Ipsen SA, H1 2017 156 Head And Neck Cancer - Pipeline by IRX Therapeutics Inc, H1 2017 156 Head And Neck Cancer - Pipeline by ISA Pharmaceuticals BV, H1 2017 157 Head And Neck Cancer - Pipeline by ISU ABXIS Co Ltd, H1 2017 157 Head And Neck Cancer - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2017 158 Head And Neck Cancer - Pipeline by Jiangsu Kanion Pharmaceutical Co Ltd, H1 2017 158 Head And Neck Cancer - Pipeline by Johnson & Johnson, H1 2017 159 Head And Neck Cancer - Pipeline by Juno Therapeutics Inc, H1 2017 159 Head And Neck Cancer - Pipeline by Kite Pharma Inc, H1 2017 160 Head And Neck Cancer - Pipeline by Kura Oncology Inc, H1 2017 160 Head And Neck Cancer - Pipeline by Laboratoires Pierre Fabre SA, H1 2017 161 Head And Neck Cancer - Pipeline by LATITUDE Pharmaceuticals Inc, H1 2017 161 Head And Neck Cancer - Pipeline by Lion Biotechnologies Inc, H1 2017 162 Head And Neck Cancer - Pipeline by Loxo Oncology Inc, H1 2017 162 Head And Neck Cancer - Pipeline by Lytix Biopharma AS, H1 2017 163 Head And Neck Cancer - Pipeline by Mabion SA, H1 2017 163 Head And Neck Cancer - Pipeline by MacroGenics Inc, H1 2017 164 Head And Neck Cancer - Pipeline by Marsala Biotech Inc, H1 2017 164 Head And Neck Cancer - Pipeline by Mateon Therapeutics Inc, H1 2017 165 Head And Neck Cancer - Pipeline by MaxiVAX SA, H1 2017 165 Head And Neck Cancer - Pipeline by Meabco A/S, H1 2017 166 Head And Neck Cancer - Pipeline by MedImmune LLC, H1 2017 167 Head And Neck Cancer - Pipeline by Merck & Co Inc, H1 2017 168 Head And Neck Cancer - Pipeline by Merck KGaA, H1 2017 169 Head And Neck Cancer - Pipeline by Millennium Pharmaceuticals Inc, H1 2017 169 Head And Neck Cancer - Pipeline by Mirati Therapeutics Inc, H1 2017 170 Head And Neck Cancer - Pipeline by Moleculin Biotech Inc, H1 2017 170 Head And Neck Cancer - Pipeline by Molplex Ltd, H1 2017 171 Head And Neck Cancer - Pipeline by NanoCarrier Co Ltd, H1 2017 171 Head And Neck Cancer - Pipeline by NantKwest Inc, H1 2017 172 Head And Neck Cancer - Pipeline by Natco Pharma Ltd, H1 2017 172 Head And Neck Cancer - Pipeline by NeoImmuneTech Inc, H1 2017 173 Head And Neck Cancer - Pipeline by Neonc Technologies Inc, H1 2017 173 Head And Neck Cancer - Pipeline by Neumedicines Inc, H1 2017 174 Head And Neck Cancer - Pipeline by Northwest Biotherapeutics Inc, H1 2017 174 Head And Neck Cancer - Pipeline by Novartis AG, H1 2017 175 Head And Neck Cancer - Pipeline by Noxopharm Ltd, H1 2017 175 Head And Neck Cancer - Pipeline by Oncobiologics Inc, H1 2017 176 Head And Neck Cancer - Pipeline by Oncolys BioPharma Inc, H1 2017 176 Head And Neck Cancer - Pipeline by Onconova Therapeutics Inc, H1 2017 177
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
